|
JSM Activity #222This is the preliminary program for the 2005 Joint Statistical Meetings in Minneapolis, Minnesota. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2005); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions. To View the Program: You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time. |
|
|
Legend: = Applied Session,
= Theme Session,
= Presenter |
222 | Tue, 8/9/05, 8:30 AM - 10:20 AM | MCC-200 H |
Non-inferiority: Paving the Way To the Future - Topic Contributed - Papers | ||
Biopharmaceutical Section, WNAR | ||
Organizer(s): Sofia Paul, Eli Lilly and Company | ||
Chair(s): Scott M. Berry, Berry Consultants LLC | ||
8:35 AM | Intent-to-treat Analyses of Noninferiority Studies — Brian Wiens, Amgen, Inc.; William Zhao, Fujisawa Healthcare, Inc. | |
8:55 AM | Issues To Consider when Constructing a Noninferiority Analysis — Mark Rothmann, U.S. Food and Drug Administration | |
9:15 AM | Arbitrary Noninferiority Margins for Active-controlled Trials — Patrick Peterson, Eli Lilly and Company | |
9:35 AM | Measuring Risk-benefit as Primary Endpoint To Assess Two Non-inferior Drugs in Cancer Patients — Sofia Paul, Eli Lilly and Company | |
9:55 AM | Disc: Clet Niyikiza, GlaxoSmithKline | |
10:15 AM | Floor Discussion | |
JSM 2005
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |